| Identification | Back Directory | [Name]
4-Thiazolecarboxamide, N-(2-benzoylphenyl)-2-[(1S)-2-methyl-1-[(3,4,5-trimethoxybenzoyl)amino]propyl]- | [CAS]
1609138-51-3 | [Synonyms]
TTT-28
TTT28,TTT 28
4-Thiazolecarboxamide, N-(2-benzoylphenyl)-2-[(1S)-2-methyl-1-[(3,4,5-trimethoxybenzoyl)amino]propyl]- | [Molecular Formula]
C31H31N3O6S | [MDL Number]
MFCD32174247 | [MOL File]
1609138-51-3.mol | [Molecular Weight]
573.66 |
| Chemical Properties | Back Directory | [Boiling point ]
653.2±55.0 °C(Predicted) | [density ]
1.266±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
10.75±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
TTT-28 is a synthesized thiazole-valine peptidomimetic, a novel selective inhibitor of ABCB1 (P-gp/MDR1) with high efficacy and low toxicity, which reverses the ATP-binding cassette sub-family B member 1 (ABCB1)-mediated multidrug resistance (MDR) by selectively blocking the efflux function of ABCB1[1]. | [in vivo]
TTT-28 (deliver orally; 30 mg/kg; every 3 rd day; 18 days) potentiates the anticancer activity of paclitaxel due to its inhibitory effect on the efflux function of ABCB1, it enhances the inhibitory effect of paclitaxel on the growth of SW620/Ad300 tumor and promoted apoptosis[1]. | Animal Model: | 5-10 week Male athymic NCR (nu/nu) nude mice ABCB1 overexpressing tumor xenograft model with SW620/Ad300 cells | | Dosage: | 30?mg/kg | | Administration: | Deliver orally; every 3rd day; 18 days | | Result: | Lead to higher intratumoral accumulation of paclitaxel in tumors. |
| [storage]
Store at -20°C | [References]
[1] Wang YJ, et al. Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1. Sci Rep. 2017 Feb 9;7:42106. DOI:10.1038/srep42106 |
|
|